With a pump and sensor, you may be up to 4 times more likely to reach your target levels1 and help lower the risk of long-term complications2,3
reduced up to 54%4
reduced up to 41%4
reduced up to 63%
reduced up to 60%4
Original Medicare refers to Medicare Part A and Part B. You will upon eligibility have the opportunity to enroll with Medicare Part A for hospitalization and with Part B for medical equipment coverage such as Medtronic insulin pump, pump supplies, and sensors.
You also have the option to choose a Medicare Advantage Plan (Part C) instead of original Medicare to cover your Medtronic insulin pump, pump supplies, and sensors. Medicare Advantage is an “all in one” alternative to Original Medicare. If you’re planning on signing up for a Medicare Advantage plan, please confirm the specific details for coverage with the company that you select to understand whether they cover Medtronic supplies. Supplies include infusion sets, reservoirs, sensors, and test strips.
For more information on Medicare, please visit www.medicare.gov.
This will depend. Check with your current healthcare provider to make sure they are enrolled as a Medicare provider. Only providers registered with Medicare can prescribe covered products to individuals enrolled in Medicare.
Yes, an insulin pump system and supplies can be covered when specific criteria are met.
For a pump, CGM, and ongoing supplies to be covered, Medtronic will request for your healthcare provider to send us written documentation which should include:
Some additional blood tests from a lab may be required. Your healthcare provider may order various lab tests including a fasting C-Peptide, a fasting blood glucose test and/or an “Islet Cell Autoantibody”. We can help guide you through the process if you call 1-877-585-0158 on Monday-Friday, 8 AM-6 PM Central Time.
If any issues occur with your pump, call our 24-Hour Technical Support team at 1-800-646-4633, option 1.
If you would like to find out the warranty status of your pump or discuss your upgrade options, call 1-800-646-4633, option 3 on Monday-Friday, 8 AM-6 PM Central Time.
To check your current warranty status online, visit www.Diabetes.shop/devices and sign into your account. If you don’t have an account created, you can create one here. Note: you do not have to be receiving supplies from Medtronic in order to create an account.
Yes, CMS (Centers for Medicare) has expanded CGM coverage* for Medicare customers. Starting February 28, 2022 customers will be able to order CGM and sensors through Medicare for Medtronic integrated systems.
Guardian™ Sensor 3 will now be covered under traditional Medicare insurance coverage when used as part of a MiniMed™ pump system.
No, the Guardian™ Connect system will not be covered through Medicare because it does not have a durable receiver to meet Medicare benefit requirements. The CGM Access Discount program will still be available for qualifying individuals wanting Guardian™ Connect and who do not have coverage. Terms and conditions apply.
Yes, the CGM order process is the same as for pump supplies. You are able to get the CGM transmitter and glucose sensors through Medicare. If you would like to place an order today, you can do so at www.Diabetes.shop or contact us at 1-800-646-4633, option 2 (Monday-Friday 8 AM- 6 PM Central Time).
Yes. Medicare customers are allowed to be enrolled in scheduled orders, but before orders are released, we will need to contact you to ensure the supplies are still needed.
This is a Medicare DME benefit under Medicare Part B.
Under the CGM Access Discount program, patients pay $60 per month for a box of sensors plus $180 per year for a transmitter. This cost averages out to $75 per month for sensors and transmitter combined. Medicare has not yet issued their specific guidelines on cost. Your cost will ultimately depend on whether you are in original Medicare or Medicare Advantage plan.
Direct customers can:
We recommend setting up scheduled orders through either of these options which will create automatic orders based on your prescription.
Place orders when you have one month of supplies left to allow plenty of time for us to collect documents and process the order.
Distributor customers can:
Yes, if utilizing a Medtronic pump system, you can receive coverage through your Medicare insurance.
Medicare allows reorders every 90 days. However, they don’t allow suppliers to ship supply orders until you have 11 days or less of supplies on hand. We will contact you within 14 days of supply shipments to make sure that the items are still needed.
Yes, if you receive supplies directly from Medtronic you may place orders by enrolling in “scheduled orders” online at www.Diabetes.shop or by speaking with a member of the Supply Management Team at 1-800-646-4633, option 2 on Monday-Friday, from 8 AM-6 PM Central Time.
We will still need to speak with you within two weeks before shipping to confirm the amount of supplies that you have on hand.
If you receive your orders through a Distributor, please contact them directly.
To speak with a Medtronic teammate who specializes in Medicare, call 1-877-585-0158 on Monday-Friday, 8 AM-6 PM Central Time.
You can also review Medicare resources at www.medicare.gov or by calling 1-800-MEDICARE (1-800-633-4227).
The MiniMed™ 770G insulin pump system automatically adjusts background insulin every 5 minutes.† Using real-time glucose readings, the system is able to calculate a personalized amount of insulin to deliver based on your needs.
The MiniMed™ 630G insulin pump delivers precise doses of insulin to your body. When combined with our CGM, it takes action for you with the SmartGuard™ Suspend on low feature - providing protection that can help keep your glucose levels stable.∆ ,‡
If you’d like some foundational understanding of what it may mean to sign up for Medicare, we recommend visiting the Medicare website or calling 1-800-MEDICARE (1-800-633-4227).
To make things easier, sign up for scheduled orders for ongoing shipments. We will still need to speak with you before the shipment is sent.
If you prefer, you can place your order online at www.Diabetes.shop or by phone.
To speak with a Medtronic team member who can answer any other questions, call 1-877-585-0158.
1. Doyle EA, Weinzimer SA, Steffen AT, Ahern JAH, Vincent M, Tamborlane WV. A randomized prospective trial comparing the efficacy of insulin pump therapy with multiple daily injections using insulin glargine. Diabetes Care. 2004;27(7):1554–1558.
2. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care. 1996;19:324–327.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
† Refers to SmartGuard™ Auto Mode. Some interaction required. Individual results may vary.
∆ WARNING: Do not use the Suspend on low feature to prevent or treat low glucose. Always confirm your sensor glucose reading using your BG meter, and follow the instructions of your healthcare professional to treat low glucose. Using Suspend on low alone to prevent or treat low glucose may result in prolonged hypoglycemia.
‡ Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–320.
Important Safety Information: MiniMed™ 770G System With SmartGuard™ Technology
The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G System includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose values (SG) and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 770G System consists of the following devices: MiniMed™ 770G Insulin Pump, the Guardian™ Link (3) Transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the AccuChek®Guide Test Strips. The system requires a prescription.
The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the SmartGuard™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard™ Auto Mode.
WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safetyinformation#minimed-770g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library
Important Safety Information: MiniMed™ 630G System
Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. MiniMed™ 630G system is approved for ages 14 years or older with Guardian™ Sensor 3 and MiniMed™ 630G system is approved for ages 16 years or older with Enlite™ sensor. Both systems require a prescription. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR®NEXT LINK 2.4 meter is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK 2.4 meter, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed™ 630G system is not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.
WARNING: The SmartGuard™ Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard feature, it is important to read the SmartGuard™ feature information in the User Guide and discuss proper use of the feature with your healthcare provider.
See important safety information and the appropriate user guides for additional important details.
Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.